Peptide
Reference library
Educational peptide reference — research use only.
Research & educational use only
For laboratory and educational research only. Not for human or veterinary consumption. This is not medical advice. Always follow applicable laws and consult qualified professionals.
The calculator performs unit math for research reference. It must not be used to plan or guide dosing in humans or animals. Verify all figures independently in your lab protocol.
Cagrilintide
A long-acting amylin analog studied in obesity and metabolic research.
- Half-life (approx.)
- ~6–8 days (approx., subQ)
- Diluent
- Bacteriostatic water (0.9% benzyl alcohol)
- Common vials
- 2, 5, 10 mg
Half-life figures are literature approximations for educational reference — not pharmacokinetic advice.
Overview
Cagrilintide is a long-acting amylin analog co-investigated with GLP-1 agonists for synergistic satiety and weight-loss endpoints. Phase trials examine combination protocols versus monotherapy in metabolic research cohorts. Long-acting amylin analog in phase obesity research, often paired with GLP-1 class agents.
Structure & identity
Long-acting amylin analog (acylated peptide)
- Sequence / structure
- Long-acting amylin analog (acylated peptide)
Status: Investigational; studied in combination with semaglutide.
Mechanism
Long-acting amylin analog that slows gastric emptying and reduces food intake synergistically with GLP-1. Gastric emptying delay and satiety signaling complement incretin receptor activation.
Studies & clinical programs
Phase 2 obesity trials
Published research models
- Peer-reviewed literature documents endpoints under Phase 2 obesity trials experimental designs.
Amylin receptor binding assays
Published research models
- Peer-reviewed literature documents endpoints under Amylin receptor binding assays experimental designs.
Research models in literature
- Phase 2 obesity trials
- Amylin receptor binding assays
Literature highlights
- Long-acting amylin analog slows gastric emptying in phase 2 obesity research.
- Synergistic weight and glycemic endpoints studied with semaglutide (CagriSema program).
- Amylin and calcitonin receptor binding characterized in receptor pharmacology assays.
Combination research notes
Studied with semaglutide (CagriSema) in clinical research.
Key targets & pathways
Research areas
Routes in research literature
Also known as
Stability & storage phases
| Phase | Condition | Guidance |
|---|---|---|
| Lyophilized | Sealed vial, refrigerated (2–8 °C) | Intact lyophilized cake or powder is typically stable for months to years per published stability data; protect from moisture, light, and repeated freeze-thaw of the dry vial. |
| Reconstituted | Bacteriostatic water (0.9% benzyl alcohol), refrigerated | Most aqueous peptide solutions remain usable for approximately 2–4 weeks refrigerated; verify published stability data and label with reconstitution date. |
| Working aliquots | Pre-drawn syringes or microtubes, frozen (−20 °C) | Aliquot promptly after mixing to limit freeze-thaw cycles on the main vial; thaw once and use to reduce protease-mediated degradation. |
Stability windows are formulation-dependent — verify published data and your lab SOP.
Reconstitution reference table
| Vial (mg) | Diluent (mL) | mcg/mL | Units @ 100 mcg | Units @ 250 mcg | Units @ 500 mcg |
|---|---|---|---|---|---|
| 2 | 2 | 1000.0 | 10 | 25 | 50 |
| 5 | 2 | 2500.0 | 4 | 10 | 20 |
| 10 | 2 | 5000.0 | 2 | 5 | 10 |
U-100 insulin syringe scale (100 units = 1 mL). Illustrative only — not dosing guidance.
Reconstitution steps
- Allow vial to reach room temperature (15–30 min)
- Swab rubber stopper with alcohol prep pad
- Draw calculated bacteriostatic water into syringe
- Inject diluent slowly down vial wall — do not spray directly onto cake
- Gently swirl until fully dissolved — do not shake vigorously
- Label with date, concentration, and diluent volume
- Refrigerate and use within your lab stability window
Reconstituted per research protocol; often combined with GLP-1 agonists in studies.
Laboratory record checklist
- Compound identity recorded in lab notebook (name, lot, preparation date)
- Analytical identity cross-checked against published sequence or structure
- Potency or concentration documented from analytical certificate when available
- Purity or HPLC data filed when provided with research material
- Appearance noted: intact lyophilized cake or uniform powder
- Sterility / endotoxin report archived when available
- Storage temperature applied immediately per published stability guidance